239 related articles for article (PubMed ID: 18524891)
1. Deregulation of a STAT3-interleukin 8 signaling pathway promotes human glioblastoma cell proliferation and invasiveness.
de la Iglesia N; Konopka G; Lim KL; Nutt CL; Bromberg JF; Frank DA; Mischel PS; Louis DN; Bonni A
J Neurosci; 2008 Jun; 28(23):5870-8. PubMed ID: 18524891
[TBL] [Abstract][Full Text] [Related]
2. STAT3-iNOS Signaling Mediates EGFRvIII-Induced Glial Proliferation and Transformation.
Puram SV; Yeung CM; Jahani-Asl A; Lin C; de la Iglesia N; Konopka G; Jackson-Grusby L; Bonni A
J Neurosci; 2012 Jun; 32(23):7806-18. PubMed ID: 22674257
[TBL] [Abstract][Full Text] [Related]
3. Identification of a PTEN-regulated STAT3 brain tumor suppressor pathway.
de la Iglesia N; Konopka G; Puram SV; Chan JA; Bachoo RM; You MJ; Levy DE; Depinho RA; Bonni A
Genes Dev; 2008 Feb; 22(4):449-62. PubMed ID: 18258752
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of the JAK-2/STAT3 signaling pathway impedes the migratory and invasive potential of human glioblastoma cells.
Senft C; Priester M; Polacin M; Schröder K; Seifert V; Kögel D; Weissenberger J
J Neurooncol; 2011 Feb; 101(3):393-403. PubMed ID: 20589525
[TBL] [Abstract][Full Text] [Related]
5. ARL4C stabilized by AKT/mTOR pathway promotes the invasion of PTEN-deficient primary human glioblastoma.
Chen Q; Weng HY; Tang XP; Lin Y; Yuan Y; Li Q; Tang Z; Wu HB; Yang S; Li Y; Zhao XL; Fu WJ; Niu Q; Feng H; Zhang X; Wang Y; Bian XW; Yao XH
J Pathol; 2019 Feb; 247(2):266-278. PubMed ID: 30357833
[TBL] [Abstract][Full Text] [Related]
6. PI3K/Akt and Stat3 signaling regulated by PTEN control of the cancer stem cell population, proliferation and senescence in a glioblastoma cell line.
Moon SH; Kim DK; Cha Y; Jeon I; Song J; Park KS
Int J Oncol; 2013 Mar; 42(3):921-8. PubMed ID: 23314408
[TBL] [Abstract][Full Text] [Related]
7. Doubles game: Src-Stat3 versus p53-PTEN in cellular migration and invasion.
Mukhopadhyay UK; Mooney P; Jia L; Eves R; Raptis L; Mak AS
Mol Cell Biol; 2010 Nov; 30(21):4980-95. PubMed ID: 20733006
[TBL] [Abstract][Full Text] [Related]
8. A novel PTEN/mutant p53/c-Myc/Bcl-XL axis mediates context-dependent oncogenic effects of PTEN with implications for cancer prognosis and therapy.
Huang X; Zhang Y; Tang Y; Butler N; Kim J; Guessous F; Schiff D; Mandell J; Abounader R
Neoplasia; 2013 Aug; 15(8):952-65. PubMed ID: 23908595
[TBL] [Abstract][Full Text] [Related]
9. Glioma cell VEGFR-2 confers resistance to chemotherapeutic and antiangiogenic treatments in PTEN-deficient glioblastoma.
Kessler T; Sahm F; Blaes J; Osswald M; Rübmann P; Milford D; Urban S; Jestaedt L; Heiland S; Bendszus M; Hertenstein A; Pfenning PN; Ruiz de Almodóvar C; Wick A; Winkler F; von Deimling A; Platten M; Wick W; Weiler M
Oncotarget; 2015 Oct; 6(31):31050-68. PubMed ID: 25682871
[TBL] [Abstract][Full Text] [Related]
10. PTEN signaling pathways in glioblastoma.
Koul D
Cancer Biol Ther; 2008 Sep; 7(9):1321-5. PubMed ID: 18836294
[TBL] [Abstract][Full Text] [Related]
11. Differential SKIP expression in PTEN-deficient glioblastoma regulates cellular proliferation and migration.
Davies EM; Kong AM; Tan A; Gurung R; Sriratana A; Bukczynska PE; Ooms LM; McLean CA; Tiganis T; Mitchell CA
Oncogene; 2015 Jul; 34(28):3711-27. PubMed ID: 25241900
[TBL] [Abstract][Full Text] [Related]
12. Interactions between PTEN and the c-Met pathway in glioblastoma and implications for therapy.
Li Y; Guessous F; DiPierro C; Zhang Y; Mudrick T; Fuller L; Johnson E; Marcinkiewicz L; Engelhardt M; Kefas B; Schiff D; Kim J; Abounader R
Mol Cancer Ther; 2009 Feb; 8(2):376-85. PubMed ID: 19190120
[TBL] [Abstract][Full Text] [Related]
13. STAT3 regulation of glioblastoma pathogenesis.
de la Iglesia N; Puram SV; Bonni A
Curr Mol Med; 2009 Jun; 9(5):580-90. PubMed ID: 19601808
[TBL] [Abstract][Full Text] [Related]
14. Mammalian target of rapamycin inhibition promotes response to epidermal growth factor receptor kinase inhibitors in PTEN-deficient and PTEN-intact glioblastoma cells.
Wang MY; Lu KV; Zhu S; Dia EQ; Vivanco I; Shackleford GM; Cavenee WK; Mellinghoff IK; Cloughesy TF; Sawyers CL; Mischel PS
Cancer Res; 2006 Aug; 66(16):7864-9. PubMed ID: 16912159
[TBL] [Abstract][Full Text] [Related]
15. SH3GL3 acts as a novel tumor suppressor in glioblastoma tumorigenesis by inhibiting STAT3 signaling.
Nie Z; Cai S; Wei Z; Li Y; Bian L; Wang C; Wang X; Wang C
Biochem Biophys Res Commun; 2021 Mar; 544():73-80. PubMed ID: 33524871
[TBL] [Abstract][Full Text] [Related]
16. PTEN deficiency reprogrammes human neural stem cells towards a glioblastoma stem cell-like phenotype.
Duan S; Yuan G; Liu X; Ren R; Li J; Zhang W; Wu J; Xu X; Fu L; Li Y; Yang J; Zhang W; Bai R; Yi F; Suzuki K; Gao H; Esteban CR; Zhang C; Izpisua Belmonte JC; Chen Z; Wang X; Jiang T; Qu J; Tang F; Liu GH
Nat Commun; 2015 Dec; 6():10068. PubMed ID: 26632666
[TBL] [Abstract][Full Text] [Related]
17. PTEN suppresses hyaluronic acid-induced matrix metalloproteinase-9 expression in U87MG glioblastoma cells through focal adhesion kinase dephosphorylation.
Park MJ; Kim MS; Park IC; Kang HS; Yoo H; Park SH; Rhee CH; Hong SI; Lee SH
Cancer Res; 2002 Nov; 62(21):6318-22. PubMed ID: 12414663
[TBL] [Abstract][Full Text] [Related]
18. The interference of Notch1 target Hes1 affects cell growth, differentiation and invasiveness of glioblastoma stem cells through modulation of multiple oncogenic targets.
Cenciarelli C; Marei HE; Zonfrillo M; Casalbore P; Felsani A; Giannetti S; Trevisi G; Althani A; Mangiola A
Oncotarget; 2017 Mar; 8(11):17873-17886. PubMed ID: 28157712
[TBL] [Abstract][Full Text] [Related]
19. Antitumor activity of rapamycin in a Phase I trial for patients with recurrent PTEN-deficient glioblastoma.
Cloughesy TF; Yoshimoto K; Nghiemphu P; Brown K; Dang J; Zhu S; Hsueh T; Chen Y; Wang W; Youngkin D; Liau L; Martin N; Becker D; Bergsneider M; Lai A; Green R; Oglesby T; Koleto M; Trent J; Horvath S; Mischel PS; Mellinghoff IK; Sawyers CL
PLoS Med; 2008 Jan; 5(1):e8. PubMed ID: 18215105
[TBL] [Abstract][Full Text] [Related]
20. HDAC7 inhibition resets STAT3 tumorigenic activity in human glioblastoma independently of EGFR and PTEN: new opportunities for selected targeted therapies.
Peixoto P; Blomme A; Costanza B; Ronca R; Rezzola S; Palacios AP; Schoysman L; Boutry S; Goffart N; Peulen O; Maris P; Di Valentin E; Hennequière V; Bianchi E; Henry A; Meunier P; Rogister B; Muller RN; Delvenne P; Bellahcène A; Castronovo V; Turtoi A
Oncogene; 2016 Aug; 35(34):4481-94. PubMed ID: 26853466
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
